143 related articles for article (PubMed ID: 32901316)
1. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
Bergman J; Burman J; Bergenheim T; Svenningsson A
J Neurol; 2021 Feb; 268(2):651-657. PubMed ID: 32901316
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Neurology; 2018 Nov; 91(20):e1893-e1901. PubMed ID: 30305449
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
5. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
8. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Svenningsson A; Bergman J; Dring A; Vågberg M; Birgander R; Lindqvist T; Gilthorpe J; Bergenheim T
Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e79. PubMed ID: 25745637
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for relapsing-remitting multiple sclerosis.
He D; Zhou H; Han W; Zhang S
Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
12. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
13. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.
Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
Fluids Barriers CNS; 2020 Jul; 17(1):49. PubMed ID: 32727487
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for secondary progressive multiple sclerosis: a case series.
Rommer PS; Patejdl R; Winkelmann A; Benecke R; Zettl UK
CNS Drugs; 2011 Jul; 25(7):607-13. PubMed ID: 21699272
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
17. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the efficacy and safety of Zytux
Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
[TBL] [Abstract][Full Text] [Related]
20. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Naismith RT; Piccio L; Lyons JA; Lauber J; Tutlam NT; Parks BJ; Trinkaus K; Song SK; Cross AH
Neurology; 2010 Jun; 74(23):1860-7. PubMed ID: 20530322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
